The FDA has rescinded the marketing denial orders (MDOs) issued to JUUL Labs Inc., partially due to new case law and further information provided by JUUL. This rescission returns the applications to pending status and does not indicate whether they will be authorized or denied. The FDA continues its substantive review of the applications, adhering to its regulations, which limit the disclosure of pending application content. Related: E-Cigarette Maker Juul’s Financial Rescue Marred by Allegation
A Relative Strength Rating upgrade for Altria Group shows improving technical performance. Will it continue?
In this article, we will take a look at some of the best dividend stocks with over 7% yield according to hedge funds. Altria Group, Inc. (NYSE:MO) topped our list of the 10 Best Dividend Stocks with 7+% Yield and we have analyzed the stock in detail. High dividend yields are attractive. They show the […]